CoChat

GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes

Araki, T., Hirayama, M., Hiroi, S., Kaku, K. · 2012 · Diabetes, Obesity and Metabolism
Cited by 96

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aim: Free fatty acids act as signalling molecules for modulating insulin secretion, and their insulinotropic effects are glucose‐dependent and mediated through G protein‐coupled receptor 40 (GPR40). This mechanism is a potential target for new treatments for managing diabetes. In this study, we present the first clinical data for TAK‐875, a novel highly selective, orally bioavailable GPR40 agonist, in Japanese patients with type 2 diabetes insufficiently controlled by diet or exercise therapy. Methods: This was an exploratory phase II, multicentre, randomized, double‐blind, parallel group study comparing the efficacy and tolerability of TAK‐875 100 and 400 mg, and placebo, all administered once daily for 2 weeks. Results: After 2 weeks of treatment, TAK‐875 produced marked glucose lowering effects in a 75 g oral glucose tolerance test (OGTT) as evidenced by mean ± SE intergroup differences in plasma glucose AUC 0–3 h of −12.98 ± 1.48 (p < 0.0001) and −8.12 ± 1.49 mmol·h/l (p < 0.0001), for TAK‐875 400 mg vs. placebo and TAK‐875 100 mg vs. placebo, respectively, and 2 h plasma glucose [−4.95 ± 0.71 (p < 0.0001) and −3.21 ± 0.71 mmol/l (p < 0.0001), respectively]. This was accompanied by a significant increase in insulin AUC 0–3 h [34.68 ± 12.16 (p < 0.01) and 31.49 ± 12.20 (p < 0 · 05) µIU·h/ml, respectively]. Improvement in glycaemic profile was mirrored by a significant change in fasting plasma glucose [−2.37 ± 0·27 (p < 0.0001) and −1.88 ± 0.27 mmol/l (p < 0.0001), respectively]. No cases of hypoglycaemia were observed despite the significant reduction in plasma glucose. Conclusions: These exploratory findings provide evidence of the glucose‐dependent insulinotropic potential of the GPR40 agonist TAK‐875, and the promising clinical changes support future longer term clinical investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01525.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 96

Metadata

Authors
Araki, T., Hirayama, M., Hiroi, S., & Kaku, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-12-22
Volume
14
Issue
3
Pages
271-278
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1985487963
Cited by
96
References
7
FWCI
9.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01525.x
The paper
Araki, T., Hirayama, M., Hiroi, S., & Kaku, K. (2012). GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01525.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.